We selected LUAD, BRCA, and colon adenocarcinoma (COAD) in vitro models together with an additional PCa cell line (LNCaP) to test the effect of LIG1 loss in combination with PARPi treatment. Here, LIG1 is linked to colon adenocarcinoma.